Allogene Therapeutics, Inc. (ALLO) News
Track canonical SquawkNews coverage tagged to ALLO, Allogene Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ALLO advances cema-cel and ALLO-329 with strong interim data
ALLO says its cema-cel and ALLO-329 programs are advancing with strong interim data and broader MRD testing adoption. Commercial launch planning is underway, and its financial runway extends into 2029.
EQUITY | Sep 09, 2026, 01:52 PM UTC
L
ALLO: Cema-cel demonstrates strong MRD clearance, with major clinical and commercial milestones ahead
Significant progress was reported across lead programs, with cema-cel showing strong MRD clearance and commercial planning underway. MRD testing adoption is rising, and the company is positioned ahead of competitors in t
EQUITY | Sep 09, 2026, 01:26 PM UTC
L
Allogene Therapeutics names Zachary Roberts CEO; Geoffrey Parker retires Nov 6, 2026
Allogene Therapeutics elevated Chief Medical Officer and President Zachary Roberts to CEO, succeeding David Chang. CFO Geoffrey Parker will retire Nov. 6, 2026 but remain to lead finance during an external search for a r
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
Allogene CFO Geoffrey Parker to retire effective Nov. 6
Allogene Therapeutics said CFO Geoffrey Parker will retire effective Nov. 6, adding to leadership changes after Zachary Roberts was elevated to chief executive.
EQUITY | Sep 02, 2026, 12:57 PM UTC
L
Allogene CFO Geoffrey Parker to retire Nov. 6, 2026
Allogene said Executive Vice President and Chief Financial Officer Geoffrey Parker will retire from the company effective Nov. 6, 2026.
REGULATION | Sep 02, 2026, 12:44 PM UTC
L
Allogene Therapeutics CFO to continue through Nov 6 retirement
Allogene Therapeutics will continue to serve its CFO through his retirement date of Nov 6.
EQUITY | Sep 02, 2026, 12:31 PM UTC
L
Allogene Therapeutics announces CFO Geoffrey Parker retirement
Allogene Therapeutics announced the retirement of its Chief Financial Officer, Geoffrey Parker.
EQUITY | Sep 02, 2026, 12:30 PM UTC
M
Allo Files $500M Mixed Shelf Offering
Allo files $500,000,000 mixed shelf offering
EQUITY | Aug 12, 2026, 08:24 PM UTC
L
Allogene Therapeutics Reports Q2 2026 Results
Allogene Therapeutics reports second quarter 2026 financial results and business update
EARNINGS | Aug 12, 2026, 08:05 PM UTC
L
ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
EARNINGS | Aug 04, 2026, 12:30 PM UTC
H
Allogene: No Serious Adverse Events For Cema-Cel
Allogene reports no serious adverse events for cema-cel
EQUITY | Jul 29, 2026, 12:36 PM UTC
L
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel)
ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy for large B-cell lymphoma
REGULATION | Jul 29, 2026, 12:30 PM UTC
L
ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car
ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car T for Treatment of Metastatic Solid Tumors
EQUITY | Jul 15, 2026, 01:30 PM UTC